Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Non-Hodgkin-Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06080191
What this trial is testing

Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Bambino Gesù Hospital and Research Institute 24
Early research (Phase 1)Ended earlyNCT04401020
What this trial is testing

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Who this might be right for
Neoplasm Malignant
Sanofi 47
Testing effectiveness (Phase 2)Study completedNCT00868608
What this trial is testing

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Who this might be right for
Lymphoma
Pfizer 81
Testing effectiveness (Phase 2)UnknownNCT02471391
What this trial is testing

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)

Who this might be right for
Mantle Cell Lymphoma
Peter MacCallum Cancer Centre, Australia 37
Not applicableLooking for participantsNCT06485076
What this trial is testing

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, RefractoryMultiple Myeloma Stage III+5 more
University Health Network, Toronto 144
Testing effectiveness (Phase 2)Active Not RecruitingNCT06035497
What this trial is testing

Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Who this might be right for
Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb 85
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Testing effectiveness (Phase 2)Study completedNCT03276468
What this trial is testing

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Who this might be right for
Follicular LymphomaDiffuse Large B Cell LymphomaMarginal Zone Lymphoma+1 more
The Lymphoma Academic Research Organisation 136
Early research (Phase 1)Active Not RecruitingNCT04049513
What this trial is testing

ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)

Who this might be right for
Lymphomas Non-Hodgkin's B-CellDiffuse Large B-cell Lymphoma (DLBCL)Primary Mediastinal B-cell Lymphoma (PMBCL)+3 more
Malaghan Institute of Medical Research 30
Testing effectiveness (Phase 2)UnknownNCT04337606
What this trial is testing

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

Who this might be right for
Non Hodgkin Lymphoma
Chinese PLA General Hospital 100
Testing effectiveness (Phase 2)Study completedNCT05844956
What this trial is testing

DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)

Who this might be right for
Lymphoma, Non-Hodgkin
Dizal Pharmaceuticals 17
Testing effectiveness (Phase 2)Study completedNCT03010358
What this trial is testing

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Who this might be right for
AnemiaB-Cell Prolymphocytic LeukemiaGrade 1 Follicular Lymphoma+11 more
Alexey Danilov, MD 24
Early research (Phase 1)Looking for participantsNCT06445517
What this trial is testing

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Who this might be right for
Advanced Solid TumorsRelapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited 60
Testing effectiveness (Phase 2)Study completedNCT03892421
What this trial is testing

Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma

Who this might be right for
Relapsed Non Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma
La Raza Medical Center 22
Testing effectiveness (Phase 2)Ended earlyNCT01799889
What this trial is testing

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic LeukemiaMantle Cell LymphomaDiffuse Large B-cell Lymphoma+2 more
Gilead Sciences 326
Early research (Phase 1)Study completedNCT02613598
What this trial is testing

Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

Who this might be right for
Hodgkin's LymphomaLymphoma, Non-Hodgkin
University of Michigan Rogel Cancer Center 15
Not applicableEnded earlyNCT00904514
What this trial is testing

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 241
Testing effectiveness (Phase 2)Study completedNCT05008055
What this trial is testing

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
AstraZeneca 30
Testing effectiveness (Phase 2)Study completedNCT02435849
What this trial is testing

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals 80
Testing effectiveness (Phase 2)Study completedNCT03213678
What this trial is testing

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma+30 more
National Cancer Institute (NCI) 18
Next Page